REPROCELL News (4)

Jan 21, 2022

REPROCELL spotlights the power of smarter biospecimens in new global publication

REPROCELL has published an article highlighting the power of biospecimens in EBR. Visit the news section of our website to find out more.

Oct 25, 2021

Hoth Therapeutics Extends Partnership Agreement with REPROCELL

Hoth Therapeutics has extended its partnership agreement with REPROCELL to assess the effect of the HT-003 therapeutic platform in IBD. Find out why.

Sep 15, 2021

Bioserve India to sponsor webinar hosted by the Society of Fetal Medicine

Find out more about Genetic Testing in Fetal Medicine in the upcoming REPROCELL sponsored webinar by the Society of Fetal Medicine.

Sep 02, 2021

REPROCELL signs Strategic Collaboration Agreement with TEXCELL to boost its GMP iPSC - Master Cell Bank Manufacturing Service

REPROCELL USA has launched a new service to manufacture GMP iPSC-Master Cell Banks (MCB), compliant with the regulatory standards and guidelines.

Aug 18, 2021

REPROCELL signs MSA with TEXCELL for Master Cell Bank Manufacturing

Read about REPROCELL's Master Service Agreement with TEXCELL JAPAN a TEXCELL Group Company for GMP iPSC - Master Cell Banks (MCB) Manufacturing.

Jul 05, 2021

REPROCELL highlights the power of human fresh tissue in global publication

This article explains the benefits of human fresh tissue testing in drug discovery, describing studies where these assays have helped clinical trials.

Jun 29, 2021

REPROCELL's solution for GMP iPSC development - Seed iPSC Manufacturing Suite

Read more about REPROCELL's new Seed iPSC Manufacture Suite to provide supply for the increasing demand of iPSC-derived Master Cell Banks

Jun 21, 2021

REPROCELL Launch New Testing Service for Identification of the Indian (Delta) Covid-19 variant

Reprocell will launch in Japan a new testing service of identification for Covid-19 variants including India (Delta), UK, South Africa, and Brazil variants

May 24, 2021

Completion of administration of Stemchymal to all enrolled patients in phase II clinical trial in Japan

The administrations of Stemchymal have been completed to all enrolled patients in phase II clinical trial for the treatment of SCA in Japan.

May 18, 2021

VIROCLINICS-DDL announces renewal of collaboration agreement with REPROCELL

Read more about how REPROCELL will provide sample processing services to VIROCLINICS-DDL to support several clinical research projects.

Apr 21, 2021

REPROCELL will participate at the Biotechgate Digital Partnering Event.

This is announcement REPROCELL USA and REPROCELL Europe will be attending Biotechgate Digital Partnering 2021.

Apr 19, 2021

19 April 2021 – Bioserve Biotechnologies India Pvt. Ltd. launches clinical oncology diagnostic services in India.

Read about REPROCELL Bioserve's launch of new clinical oncology diagnostic services featuring NGS-based genomic profiling, targeting a wide range of cancers

Apr 08, 2021

Launch of New Testing Service of Identification for Covid-19 Variants

REPROCELL has launched a new testing service of identification for Covid-19 variants using Allplex SARS-CoV-2 Variants I Assay manufactured by Seegene Inc.

Mar 22, 2021

REPROCELL collaborates with Blacktrace Holdings in the sales of Nadia series, single-cell analysis system, in Japan

Find out more about REPROCELL's collaboration with Blacktrace Holdings Ltd in the domestic sales of their Nadia series: a single-cell analytical system.

Mar 17, 2021

REPROCELL Regenerative Medicine Center officially certified as a manufacturing facility for cell culture products

We are pleased to announce that the REPROCELL Regenerative Medicine Center has been certified as a manufacturing facility for cell culture products.

Mar 15, 2021

Hoth Therapeutics Executes Partnership Agreement with REPROCELL to Assess the Effect of HT-003 Therapeutic Platform on Inflammatory Bowel Disease

Hoth Therapeutics has executed a partnership agreement with REPROCELL to assess the effect of its HT-003 therapeutic platform on tissue from IBD donors.

Mar 11, 2021

Corporate News